Cargando…

Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control

The caregiver perspective on pediatric attention-deficit/hyperactivity disorder (ADHD) study (CAPPA) was a web-based, cross-sectional survey of caregivers of children and adolescents (6–17 years of age) with ADHD and was conducted in 10 European countries. CAPPA included caregiver assessments of glo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fridman, Moshe, Banaschewski, Tobias, Sikirica, Vanja, Quintero, Javier, Erder, M Haim, Chen, Kristina S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315351/
https://www.ncbi.nlm.nih.gov/pubmed/28243096
http://dx.doi.org/10.2147/NDT.S121639
_version_ 1782508676660068352
author Fridman, Moshe
Banaschewski, Tobias
Sikirica, Vanja
Quintero, Javier
Erder, M Haim
Chen, Kristina S
author_facet Fridman, Moshe
Banaschewski, Tobias
Sikirica, Vanja
Quintero, Javier
Erder, M Haim
Chen, Kristina S
author_sort Fridman, Moshe
collection PubMed
description The caregiver perspective on pediatric attention-deficit/hyperactivity disorder (ADHD) study (CAPPA) was a web-based, cross-sectional survey of caregivers of children and adolescents (6–17 years of age) with ADHD and was conducted in 10 European countries. CAPPA included caregiver assessments of global medication satisfaction, global symptom control, and satisfaction with ADHD medication attributes. Overall, 2,326 caregiver responses indicated that their child or adolescent was currently receiving ADHD medication and completed the “off medication” assessment required for inclusion in the present analyses. Responses to the single-item global medication satisfaction question indicated that 88% were satisfied (moderately satisfied to very satisfied) with current medication and 18% were “very satisfied” on the single-item question. Responses to the single-item global symptom control question indicated that 47% and 19% of caregivers considered their child or adolescent’s symptoms to be “controlled” or “very well controlled”, respectively. Significant variations in response to the questions of medication satisfaction and symptom control were observed between countries. The correlation between the global medication satisfaction and global symptom control questions was 0.677 (P<0.001). Global medication satisfaction was significantly correlated (P<0.001) with all assessed medication attributes, with the highest correlations observed for symptom control (r=0.601) and effect duration (r=0.449). Correlations of medication attributes with global symptom control were generally lower than with global medication satisfaction but were all statistically significant (P<0.001). CAPPA medication satisfaction and symptom control were also significantly correlated (P<0.001) with symptom control as based on the ADHD-Rating Scale-IV symptom score and the number of bad days per month when on medication. In conclusion, caregiver responses in this European sample suggest that current treatment could potentially be improved. The observed correlations of global medication satisfaction with global symptom control and other CAPPA assessments, including medication attributes, provide support for the inter-connectivity of the medication satisfaction and symptom control.
format Online
Article
Text
id pubmed-5315351
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53153512017-02-27 Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control Fridman, Moshe Banaschewski, Tobias Sikirica, Vanja Quintero, Javier Erder, M Haim Chen, Kristina S Neuropsychiatr Dis Treat Original Research The caregiver perspective on pediatric attention-deficit/hyperactivity disorder (ADHD) study (CAPPA) was a web-based, cross-sectional survey of caregivers of children and adolescents (6–17 years of age) with ADHD and was conducted in 10 European countries. CAPPA included caregiver assessments of global medication satisfaction, global symptom control, and satisfaction with ADHD medication attributes. Overall, 2,326 caregiver responses indicated that their child or adolescent was currently receiving ADHD medication and completed the “off medication” assessment required for inclusion in the present analyses. Responses to the single-item global medication satisfaction question indicated that 88% were satisfied (moderately satisfied to very satisfied) with current medication and 18% were “very satisfied” on the single-item question. Responses to the single-item global symptom control question indicated that 47% and 19% of caregivers considered their child or adolescent’s symptoms to be “controlled” or “very well controlled”, respectively. Significant variations in response to the questions of medication satisfaction and symptom control were observed between countries. The correlation between the global medication satisfaction and global symptom control questions was 0.677 (P<0.001). Global medication satisfaction was significantly correlated (P<0.001) with all assessed medication attributes, with the highest correlations observed for symptom control (r=0.601) and effect duration (r=0.449). Correlations of medication attributes with global symptom control were generally lower than with global medication satisfaction but were all statistically significant (P<0.001). CAPPA medication satisfaction and symptom control were also significantly correlated (P<0.001) with symptom control as based on the ADHD-Rating Scale-IV symptom score and the number of bad days per month when on medication. In conclusion, caregiver responses in this European sample suggest that current treatment could potentially be improved. The observed correlations of global medication satisfaction with global symptom control and other CAPPA assessments, including medication attributes, provide support for the inter-connectivity of the medication satisfaction and symptom control. Dove Medical Press 2017-02-13 /pmc/articles/PMC5315351/ /pubmed/28243096 http://dx.doi.org/10.2147/NDT.S121639 Text en © 2017 Fridman et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Fridman, Moshe
Banaschewski, Tobias
Sikirica, Vanja
Quintero, Javier
Erder, M Haim
Chen, Kristina S
Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control
title Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control
title_full Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control
title_fullStr Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control
title_full_unstemmed Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control
title_short Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control
title_sort caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315351/
https://www.ncbi.nlm.nih.gov/pubmed/28243096
http://dx.doi.org/10.2147/NDT.S121639
work_keys_str_mv AT fridmanmoshe caregiverperspectiveonpediatricattentiondeficithyperactivitydisordermedicationsatisfactionandsymptomcontrol
AT banaschewskitobias caregiverperspectiveonpediatricattentiondeficithyperactivitydisordermedicationsatisfactionandsymptomcontrol
AT sikiricavanja caregiverperspectiveonpediatricattentiondeficithyperactivitydisordermedicationsatisfactionandsymptomcontrol
AT quinterojavier caregiverperspectiveonpediatricattentiondeficithyperactivitydisordermedicationsatisfactionandsymptomcontrol
AT erdermhaim caregiverperspectiveonpediatricattentiondeficithyperactivitydisordermedicationsatisfactionandsymptomcontrol
AT chenkristinas caregiverperspectiveonpediatricattentiondeficithyperactivitydisordermedicationsatisfactionandsymptomcontrol